Esteban Daudén, Elena Escario, Luisa Martos-Cabrera, Susana Armesto, Enrique Herrera-Acosta, David Vidal, Eva Vilarrasa, Raquel Rivera, Pablo de la Cueva, Antonio Martorell, Ferran Ballesca, Isabel Belinchón, Gregorio Carretero, Lourdes Rodríguez, Alberto Romero-Maté, J Pujol-Montcusí, Laura Salgado, Antonio Sahuquillo-Torralba, Pablo Coto-Segura, Ofelia Baniandrés, R Feltes, Josep Riera-Monroig, Jesus Garrido, Mar Llamas-Velasco
BACKGROUND: Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis. OBJECTIVE: The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC-DR) strategy and assess its safety and cost implications. METHODS: A retrospective, observational, multicenter cohort study was conducted in patients with plaque psoriasis treated with secukinumab and up to 2 years of follow-up...
January 2, 2024: International Journal of Dermatology